Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Prognostic Value of the Lung Immune Prognostic Index and an ECOG-Albumin-LIPI Nomogram in Metastatic NSCLC Patients Treated with Second- or Third-Line Nivolumab. (PubMed, J Clin Med) - Sep 16, 2026 - " LIPI was independently associated with prognosis in this cohort. Combining LIPI with ECOG and albumin may aid individualized risk assessment, pending external validation." 
Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
http://www.ncbi.nlm.nih.gov/pubmed/42739873
 
Ahmet Küçükarda; Dicle Yurdatap Koç; Ece Demirdelen
 
Sep 16, 2026
 
Prev Next